Skip to main content
Arnaud Pagès on Muck Rack

Arnaud Pagès

As seen in: Nature, MDPI, Value in Health Journal

Get in touch with Arnaud

Contact Arnaud, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangement

|
By Arnaud Pagès, Emmanuel Raffoux, Céline Berthon, Laurène Fenwarth, Cécile Pautas, Thomas Cluzeau, Delphine Lebon Verified, Madalina Uzunov, Patricio Javier Pereyra, Maël Heiblig, Jean-Valère Malfuson, Laure Farnault, Pierre-Yves Dumas, Sarah Bertoli, Sylvain Chantepie, Nathalie Auger, Audrey Bidet, Augustin Boudry, Isabelle Luquet, Romain Loyaux, Emmanuelle Clappier, Mathilde Hunault, Stephane de Botton, Arnaud Pigneux, Dominique Penther, Eric Delabesse, Raphael Itzykson, Claude Preudhomme, Hervé Dombret, Christian Récher, Nicolas Duployez, Jean-Baptiste Micol, Benoit Ducourneau, Stéphanie Struski, Matthieu Decamp, Vincent Marmouset, Julia Hieulle, Marie-Joelle Mozziconacci, Laureen Chat, Lina El-Mur, Claude Gardin
| Nature Verified
Abstract We report a large cohort of 95 adult patients with acute myeloid leukemia (AML) harboring NUP98 rearrangements (NUP98r). Patient characteristics included a young age (median 50 years [IQR 38-64]), 20% of therapy-related AML, a high WBC count (median 52×109/L), normal karyotype in 32%, FLT3-ITD in 48% and WT1 mutations in 34%. NUP98::NSD1 fusion was the most common (54%), and these patients were significantly younger (41 y vs. 61 y), had more de novo AML (94% vs.
Open in Who Shared Issue with article?

Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients - Blood Cancer Journal

|
By Christophe Willekens, Alex Bataller, Caitlin R Rausch, Nicholas Short, Koji Sasaki, Mahesh Swaminathan, Jean-Baptiste Micol, Tapan M Kadia, Farhad Ravandi, Hagop Kantarjian, Arnaud Pagès
| Nature Verified
Abstract Hypomethylating agent (HMA) plus venetoclax (VEN) regimens are standard of care in patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy. While the VEN label recommends continuous 28-day cycles, shortened VEN durations may induce similar response rates and improve tolerability. It is unknown how a VEN exposure reduced to 7 days during cycles compares to standard HMA + VEN.
Open in Who Shared Issue with article?

Opioid Reduced Anesthesia in Major Oncologic Cervicofacial Surgery: A Retrospective Study

|
By Cyrus Motamed, Lauriane Bordenave, Emma Evrard, Arnaud Pagès
| MDPI
This is an early access version, the complete PDF, HTML, and XML versions will be available soon. Open AccessArticle by Emma Evrard 1,2, Cyrus Motamed 1,*, Arnaud Pagès 3 and Lauriane Bordenave 1 1 Department of Anesthesiology, Gustave Roussy, 94805 Villejuif, France 2 Faculty of Medicine, University of Paris-Saclay, 94270 Le Kremlin Bicêtre, France 3 Department of Biostatistics and Epidemiology, Gustave Roussy, 94805 Villejuif, France * Author to whom correspondence should be addressed. J. Clin.
Open in Who Shared Issue with article?
See all 4 articles